EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro

Pauline Resnier, Stephanie David, Nolwenn Lautram, Gaëtan J R Delcroix, Anne Clavreul, Jean Pierre Benoit, Catherine Passirani

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Glioma are the most common malignant tumors of the central nervous system and remain associated with poor prognosis, despite the combination of chemotherapy and radiotherapy. EGFR targeting represents an interesting strategy to treat glioma. Indeed, a high level of endothelial growth factor receptors expression (EGFR), involved in the malignancy of the tumor, has been observed in glioma. Our strategy consisted in using EGFR siRNA entrapped into lipid nanocapsules (LNCs) via cationic liposomes. In vitro analyses on U87MG human glioma cells were performed to evaluate firstly the capacity of LNCs to efficiently deliver the siRNA and secondly the effect of EGFR siRNA targeting on U87MG proliferation. Then, the complement protein consumption was evaluated by CH50 assays to verify the suitability of the siRNA LNCs for systemic administration. The EGFR siRNA LNCs exhibited an adequate size lower than 150 nm as well as a neutral surface charge. The IC50 profile together with the 63% of protein extinction demonstrated the significant action of EGFR siRNA LNCs compared to scrambled LNCs. Dose and time-dependent survival assays showed a decrease of U87MG growth evaluated at 38%. Finally, low complement consumption demonstrated the suitability of EGFR siRNA LNCs for intravenous injection. In conclusion, EGFR siRNA LNCs demonstrated their capacity to efficiently encapsulate and deliver siRNA into U87MG human glioma cells, and will therefore be usable in the future for in vivo evaluation.

Original languageEnglish (US)
Pages (from-to)748-755
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume454
Issue number2
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Nanocapsules
Vascular Endothelial Growth Factor Receptor
Glioma
Small Interfering RNA
Lipids
Complement Hemolytic Activity Assay
In Vitro Techniques
Central Nervous System Neoplasms
Combination Drug Therapy
Liposomes
Intravenous Injections
Inhibitory Concentration 50
Neoplasms
Complement System Proteins
Radiotherapy

Keywords

  • Brain tumor
  • CH50
  • Gene therapy
  • Nanomedicine
  • U87MG

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Resnier, P., David, S., Lautram, N., Delcroix, G. J. R., Clavreul, A., Benoit, J. P., & Passirani, C. (2013). EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro. International Journal of Pharmaceutics, 454(2), 748-755. https://doi.org/10.1016/j.ijpharm.2013.04.001

EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro. / Resnier, Pauline; David, Stephanie; Lautram, Nolwenn; Delcroix, Gaëtan J R; Clavreul, Anne; Benoit, Jean Pierre; Passirani, Catherine.

In: International Journal of Pharmaceutics, Vol. 454, No. 2, 2013, p. 748-755.

Research output: Contribution to journalArticle

Resnier, P, David, S, Lautram, N, Delcroix, GJR, Clavreul, A, Benoit, JP & Passirani, C 2013, 'EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro', International Journal of Pharmaceutics, vol. 454, no. 2, pp. 748-755. https://doi.org/10.1016/j.ijpharm.2013.04.001
Resnier, Pauline ; David, Stephanie ; Lautram, Nolwenn ; Delcroix, Gaëtan J R ; Clavreul, Anne ; Benoit, Jean Pierre ; Passirani, Catherine. / EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro. In: International Journal of Pharmaceutics. 2013 ; Vol. 454, No. 2. pp. 748-755.
@article{02a3b0cca6b84115af22f05c21860385,
title = "EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro",
abstract = "Glioma are the most common malignant tumors of the central nervous system and remain associated with poor prognosis, despite the combination of chemotherapy and radiotherapy. EGFR targeting represents an interesting strategy to treat glioma. Indeed, a high level of endothelial growth factor receptors expression (EGFR), involved in the malignancy of the tumor, has been observed in glioma. Our strategy consisted in using EGFR siRNA entrapped into lipid nanocapsules (LNCs) via cationic liposomes. In vitro analyses on U87MG human glioma cells were performed to evaluate firstly the capacity of LNCs to efficiently deliver the siRNA and secondly the effect of EGFR siRNA targeting on U87MG proliferation. Then, the complement protein consumption was evaluated by CH50 assays to verify the suitability of the siRNA LNCs for systemic administration. The EGFR siRNA LNCs exhibited an adequate size lower than 150 nm as well as a neutral surface charge. The IC50 profile together with the 63{\%} of protein extinction demonstrated the significant action of EGFR siRNA LNCs compared to scrambled LNCs. Dose and time-dependent survival assays showed a decrease of U87MG growth evaluated at 38{\%}. Finally, low complement consumption demonstrated the suitability of EGFR siRNA LNCs for intravenous injection. In conclusion, EGFR siRNA LNCs demonstrated their capacity to efficiently encapsulate and deliver siRNA into U87MG human glioma cells, and will therefore be usable in the future for in vivo evaluation.",
keywords = "Brain tumor, CH50, Gene therapy, Nanomedicine, U87MG",
author = "Pauline Resnier and Stephanie David and Nolwenn Lautram and Delcroix, {Ga{\"e}tan J R} and Anne Clavreul and Benoit, {Jean Pierre} and Catherine Passirani",
year = "2013",
doi = "10.1016/j.ijpharm.2013.04.001",
language = "English (US)",
volume = "454",
pages = "748--755",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro

AU - Resnier, Pauline

AU - David, Stephanie

AU - Lautram, Nolwenn

AU - Delcroix, Gaëtan J R

AU - Clavreul, Anne

AU - Benoit, Jean Pierre

AU - Passirani, Catherine

PY - 2013

Y1 - 2013

N2 - Glioma are the most common malignant tumors of the central nervous system and remain associated with poor prognosis, despite the combination of chemotherapy and radiotherapy. EGFR targeting represents an interesting strategy to treat glioma. Indeed, a high level of endothelial growth factor receptors expression (EGFR), involved in the malignancy of the tumor, has been observed in glioma. Our strategy consisted in using EGFR siRNA entrapped into lipid nanocapsules (LNCs) via cationic liposomes. In vitro analyses on U87MG human glioma cells were performed to evaluate firstly the capacity of LNCs to efficiently deliver the siRNA and secondly the effect of EGFR siRNA targeting on U87MG proliferation. Then, the complement protein consumption was evaluated by CH50 assays to verify the suitability of the siRNA LNCs for systemic administration. The EGFR siRNA LNCs exhibited an adequate size lower than 150 nm as well as a neutral surface charge. The IC50 profile together with the 63% of protein extinction demonstrated the significant action of EGFR siRNA LNCs compared to scrambled LNCs. Dose and time-dependent survival assays showed a decrease of U87MG growth evaluated at 38%. Finally, low complement consumption demonstrated the suitability of EGFR siRNA LNCs for intravenous injection. In conclusion, EGFR siRNA LNCs demonstrated their capacity to efficiently encapsulate and deliver siRNA into U87MG human glioma cells, and will therefore be usable in the future for in vivo evaluation.

AB - Glioma are the most common malignant tumors of the central nervous system and remain associated with poor prognosis, despite the combination of chemotherapy and radiotherapy. EGFR targeting represents an interesting strategy to treat glioma. Indeed, a high level of endothelial growth factor receptors expression (EGFR), involved in the malignancy of the tumor, has been observed in glioma. Our strategy consisted in using EGFR siRNA entrapped into lipid nanocapsules (LNCs) via cationic liposomes. In vitro analyses on U87MG human glioma cells were performed to evaluate firstly the capacity of LNCs to efficiently deliver the siRNA and secondly the effect of EGFR siRNA targeting on U87MG proliferation. Then, the complement protein consumption was evaluated by CH50 assays to verify the suitability of the siRNA LNCs for systemic administration. The EGFR siRNA LNCs exhibited an adequate size lower than 150 nm as well as a neutral surface charge. The IC50 profile together with the 63% of protein extinction demonstrated the significant action of EGFR siRNA LNCs compared to scrambled LNCs. Dose and time-dependent survival assays showed a decrease of U87MG growth evaluated at 38%. Finally, low complement consumption demonstrated the suitability of EGFR siRNA LNCs for intravenous injection. In conclusion, EGFR siRNA LNCs demonstrated their capacity to efficiently encapsulate and deliver siRNA into U87MG human glioma cells, and will therefore be usable in the future for in vivo evaluation.

KW - Brain tumor

KW - CH50

KW - Gene therapy

KW - Nanomedicine

KW - U87MG

UR - http://www.scopus.com/inward/record.url?scp=84884156153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884156153&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2013.04.001

DO - 10.1016/j.ijpharm.2013.04.001

M3 - Article

VL - 454

SP - 748

EP - 755

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 2

ER -